

**Embassy of India
Brasilia**

**India-Brazil: Strengthening Partnerships in Pharmaceutical Sector
26-27 November 2020
Press Release**

On 26 November 2020, the Embassy of India in Brasilia, in association with the Pharmaceutical Export Promotion Council of India (Pharmexcil), organized a webinar themed “India-Brazil: Strengthening Partnerships in Pharmaceutical Sector”. The focus is on opportunities for collaboration and partnership between the private sector of both countries in the pharmaceutical sector.

2. The event saw addresses by high-level officials from both India and Brazil including H.E. Mr. Suresh K. Reddy, Ambassador of India to Brazil; H.E. Mr. André Aranha Corrêa do Lago, Ambassador of Brazil to India; Mr. Antonio Elcio Franco Filho, Executive Secretary, Ministry of Health of Brazil; Mr. Antonio Barra Torres, President, ANVISA. The event also saw B2B interactions between the Indian and Brazilian companies engaged in pharmaceutical sector.

3. India is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and also supplies 62% of global demand for vaccines. India ranks 3rd worldwide for production by volume and 14th by value.


India is the only country with largest number of US-FDA compliant Pharma plants (more than 262 including APIs) outside of USA. India has more than 2000 WHO-GMP approved Pharma Plants, 253 European Directorate of Quality Medicines (EDQM) approved plants with modern state of the art Technology.

4. Overall Scenario:

- India is the source of 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs). The API industry is ranked third largest in the world contributing 57% of APIs to pre-qualified list of the WHO.
- India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK.
- Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.
- The country is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities. The domestic pharmaceuticals market turnover reached \$20.03 billion in 2019, up 9.3% from 2018, growing as penetration of health insurance and pharmacies rise.

5. Industry Scenario:

- The Indian pharmaceutical industry is currently valued at \$41 billion.
- Generic drugs, with 71% market share, form the largest segment of the Pharmaceutical industry in India. Indian pharmaceutical sector is expected to grow to US\$ 100 billion, while medical device market is expected to grow US\$ 25 billion by 2025.
- Pharmaceuticals export from India stood at US\$ 20.70 billion in Financial Year 2019-20. Pharmaceutical export includes bulk drugs, intermediates, drug formulations, biologicals, AYUSH and herbal products and surgical.
- India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30% a y-o-y to reach US\$ 100 billion by 2025.



6. India's Ranking:

- **Exports:** 20% of global generics by volume, making it the largest provider of generic medicines globally
- **Indian Pharmaceuticals market:** 3rd in terms of volume (10 % of global industry) and 14th in terms of value
- **Major Segments:** Generic Drugs, OTC Medicines and Patented Drugs
- Largest vaccine producer in the world: Over 65% of WHO demand for DPT and BCG and 90% measles vaccines supplied by India
- **Future Potential:** Indian pharmaceutical market is expected to reach USD 100 billion by 2025

7. Indian Pharma Exports to Brazil:

India's pharma exports to Brazil in FY 2019-20 were US\$ 473.10 million and grew by 4.56% when compared to pharma exports of US\$ 452.06 million in FY 2018-19. During the period Apr-Sept 2020, India's pharma exports to Brazil were 255.94 million and registered a growth by 13.14% when compared to pharma exports of US\$ 226.22 million during Apr-Sept 2019.



8. India's COVID-19 cooperation with the World:

- India received requests for Hydroxychloroquine (HCQ), paracetamol APIs and tablet supply from over 150 countries. India supplied paracetamol and HCQ to all neighbouring countries and also agreed to supply essential drugs to other nations who have been badly affected by the pandemic. India through its active international response has proved itself to be a reliable partner.
- In recognition of its continuous and effective efforts to scale up the global supply of this much-needed medicine, India has attracted widespread praise and acknowledgement across continents.
- President Jair Bolsonaro thanked Prime Minister for sending the life-saving supply of HCQ to Brazil. He was joined by other global leaders and heads of states like US President Donald Trump and Israeli Prime Minister Benjamin Netanyahu, who also thanked the Indian prime minister for shipping the drug to their countries in these testing times.
- India also went a step ahead in fulfilling its global role as a responsible member of the international community. India supplied HCQ and paracetamol tablets to several Latin American and African countries on humanitarian grounds.



Jair M. Bolsonaro ✓
@jairbolsonaro



- Nossos agradecimentos ao primeiro-ministro da Índia [@narendramodi](#), que, após nossa conversa por telefone, liberou o envio ao Brasil de um carregamento de insumos para produção de hidroxiclороquina.

[Translate Tweet](#)



8:03 AM · Apr 9, 2020 · Twitter for Android



Jair M. Bolsonaro ✓
@jairbolsonaro



Replying to [@jairbolsonaro](#)

- Um gesto honroso que poderá ajudar a salvar a vida de muitos brasileiros, e do qual jamais esqueceremos.



[Translate Tweet](#)

8:04 AM · Apr 9, 2020 · Twitter for Android



Donald J. Trump ✓
@realDonaldTrump



Extraordinary times require even closer cooperation between friends. Thank you India and the Indian people for the decision on HCQ. Will not be forgotten! Thank you Prime Minister [@NarendraModi](#) for your strong leadership in helping not just India, but humanity, in this fight!

3:11 PM · Apr 8, 2020 · Twitter for iPhone



PM of Israel ✓
@IsraeliPM

⋮

Thank you, my dear friend @narendramodi, Prime Minister of India, for sending Chloroquine to Israel.

All the citizens of Israel thank you! 🇮🇸 🇮🇳



3:37 PM · Apr 9, 2020 · TweetDeck

9. India-Brazil Common Challenges in Healthcare sector:

Brazil is the most populous country and the largest healthcare market in Latin America and the Caribbean. In 2017, Brazil's spending in health accounted for 9.5 percent of the country's GDP. With an estimated population of around 210 million inhabitants, the health expenditure per capita in Brazil averaged US\$ 1,282 in 2018. Besides health expenditure, Brazil is the nation with the highest number of hospitals in Latin America, and has one of the largest healthcare workforces in the region.

With the second largest population in the world, an increase in life expectancy and a gradually reducing death rate over the years have resulted in sharp rise in public health expenditure in India since 2014.

With India being the largest provider of generic medicines globally, and supplying affordable, quality medicines to the world, there is a tremendous scope for India and Brazil to work together to provide affordable, universal health care.

10. COVID-19 Vaccines Development in India:

As the COVID-19 pandemic shows no signs of abatement, India has granted test license permission for manufacture of COVID-19 vaccine for preclinical testing, examination and analysis to the following manufacturers in India:

1. M/s Serum Institute of India Pvt. Ltd., Pune
2. Ms. Cadila Healthcare Ltd., Ahmadabad
3. M/s Bharat Biotech International Ltd., Hyderabad
4. Biological E Ltd., Hyderabad
5. M/s Reliance Life Sciences Pvt. Ltd., Mumbai
6. M/s Aurbindo Pharma Limited, Hyderabad
7. M/s Gennova Biopharmaceuticals Limited, Pune

Recently, Bharat Biotech offered Brazil its COVID-19 vaccine that is in late-stage clinical trials and a possible technology transfer partnership. At the same time, India and Brazil are members of the Developing Countries Vaccine Manufactures Network (DCVMN) which was established with the mission of increasing the quality and availability of vaccines affordable to all.

11. Ayushman Bharat:

Ayushman Bharat is a flagship scheme of Government of India to achieve the vision of Universal Health Coverage (UHC).

Ayushman Bharat adopts a continuum of care approach, comprising of two inter-related components, which are -

- Health and Wellness Centres (HWCs)
- Pradhan Mantri Jan Arogya Yojana (PM-JAY)

In February 2018, the Government of India announced the creation of 1,50,000 Health and Wellness Centres (HWCs) . At the same time, PM-JAY is the largest health assurance scheme in the world which aims at providing a health cover of about USD 6700 per family per year for secondary and tertiary care hospitalization to over 107 million poor and vulnerable families (approximately 500 million beneficiaries). PM-JAY is fully funded by the Government and cost of implementation is shared between the Central and State Governments.

12. National Digital Health Mission:

The National Digital Health Mission aims to develop the backbone necessary to support the integrated digital health infrastructure of the country. It will bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. It is a digital health ecosystem under which every Indian citizen will now have unique health IDs, digitised health records with identifiers for doctors and health facilities. The Mission is expected to bring efficiency and transparency in healthcare services in the country.
